Origin Therapeutics To Be A Silver Sponsor For Major Psychedelics Conference, Wonderland: Miami

Wonderland: Miami is hosted by Microdose Psychedelic Insights, an Origin Therapeutics portfolio company.

Vancouver, British Columbia – October 20, 2021 – Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is announcing its participation as a silver sponsor of Wonderland: Miami, the largest in-person conference on the psychedelic medicine business. The event was organized by Microdose Psychedelic Insights (“Microdose”), a portfolio company of Origin Therapeutics.

Microdose aims to unlock the potential of psychedelics through industry events, market intelligence, original evidence-based content, strategy, and community. They work with the industry’s most influential stakeholders, some of the world’s best-known brands, and an unrivaled network of scientists, researchers, analysts, innovators, investors, and advisors.

The conference will take place on November 8th and 9th at the Adrienne Arsht Center for Performing Arts in Miami. Tickets are selling quickly. The second round of early bird tickets are available for $499 (USD).

“We are pleased to have the opportunity to participate as a silver sponsor for the historic Wonderland: Miami conference,” said Origin Therapeutics CEO, Alexander Somjen. “Microdose is truly a leader in the industry that has its finger on the pulse of the key players and trends. We look forward to participating and building connections with founders and potential new partners and investors.”

Origin Therapeutics is focused on identifying and investing in private, early-stage companies in the psychedelics industry; it is developing a diverse industry portfolio in the sector. The Company manages investments via advisory support roles to help boost portfolio company growth.

Subscribe to updates about Origin Therapeutics online at: https://originpsychedelics.com/

-##-

About Origin Therapeutics

Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify leading and emerging global companies for its portfolio that are innovating in the sector and are supported by science. Learn more: https://originpsychedelics.com/

For Further Information:

Alexander Somjen

Chief Executive Officer and Director

Origin Therapeutics Holdings Inc

www.originpsychdelics.com

info@originpsychedelics.com

For media inquiries, please contact: Brittany@Exvera.com

Forward-Looking Information and Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

‍